- Innate to present new Phase 2 data on the combination of
monalizumab, cetuximab and durvalumab in head and neck cancer in an
oral presentation
- ANKETTM to be highlighted in ESMO IO educational
session
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) announced today that it
will present new data from the Phase 2 expansion cohort (‘cohort
3’) exploring the triplet combination of monalizumab, cetuximab and
durvalumab, in first-line IO and chemo-naïve patients with
recurrent or metastatic head and neck squamous cell cancer (R/M
SCCHN) at the ESMO Immuno-oncology Congress 2021, being held
virtually from December 8-11 2021.
Monalizumab, Innate’s lead partnered asset, is a potentially
first-in-class immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells
and NK cells.
Additionally, Pr. Eric Vivier, Ph.D., DVM, Chief Scientific
Officer at Innate Pharma, will present in the NK cell biology
educational session. Details can be found below.
Presentation Details:
- Monalizumab: The oral presentation (#123MO) entitled,
“Monalizumab, cetuximab and durvalumab in first-line treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (R/M SCCHN): a phase 2 trial,” will be presented from
12:15-12:20 pm CET on December 9, 2021.
- NK cells: Prof. Vivier will discuss Innate’s
multi-specific NK cell engager platform, ANKETTM (Antibody-based NK
cell Engager Therapeutics), in the educational session entitled,
“NK cells biology and therapeutic opportunities, innate immunity,
adaptive immunity” from 11:40 – 12 pm CET on December 9, 2021.
About Monalizumab:
Monalizumab is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor-infiltrating
cytotoxic CD8+ T cells and NK cells.
NKG2A is an inhibitory checkpoint receptor for HLA-E. By
expressing HLA-E, cancer cells can protect themselves from killing
by NKG2A+ immune cells. HLA-E is frequently overexpressed in the
cancer cells of many solid tumors and hematological malignancies.
Monalizumab may re-establish a broad anti-tumor response mediated
by NK and T cells and may enhance the cytotoxic potential of other
therapeutic antibodies1.
AstraZeneca obtained full oncology rights to monalizumab in
October 2018 through a co-development and commercialization
agreement initiated in 2015. The ongoing development for
monalizumab is focused on investigating monalizumab in various
combination strategies in different malignancies.
About ANKETTM:
ANKETTM (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer. The Company’s latest
innovation, its tetra-specific ANKETTM molecule, is the first NK
cell engager technology to engage two NK cell-activating receptors
(NKp46 and CD16), a tumor antigen and the interleukin-2 receptor
(by an IL-2 variant, IL-2v), via a single molecule. This molecule
leverages the advantages of harnessing NK cell effector functions
against cancer cells and also provides proliferation and activation
signals targeted to NK cells.
In pre-clinical studies, Innate's tri-2 and tetra-specific
ANKETTM technologies promote potent NK cell activation,
cytotoxicity and efficient control of tumor growth in pre-clinical
models. This versatile fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical needs.
Innate is a pioneer in the understanding of natural killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995.The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2020, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
1 André et al, Cell 2018 2 Gauthier et al. Cell 2019
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211202005097/en/
Investors Innate
Pharma Henry Wheeler
Tel.: +33 761 88 38 74
Henry.wheeler@innate-pharma.fr
Media Innate Pharma
Tracy Rossin (Global/US) Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46
72 innate-pharma@atcg-partners.com
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024